This Market Spotlight report covers the Hypogonadism market, comprising key marketed and pipeline drugs, clinical trials, probability of success, epidemiology, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

• The approved drugs in the hypogonadism space target androgen receptors, estrogen receptor alpha, and estrogen receptor beta. These are commonly administered via the transdermal route, with a smaller number of products being available in oral, intramuscular, intranasal, sublingual/oral transmucosal, subcutaneous, and topical formulations.
• There are only two industry-sponsored drugs in active clinical development for hypogonadism, both of which are in Phase II. Therapies in development for hypogonadism target aromatase and androgen receptors. These pipeline drugs are administered via the oral route.
• The overall likelihood of approval of a Phase I hypogonadism asset is 26.9%, and the average probability a drug advances from Phase III is 72.7%. Drugs, on average, take 8.9 years from Phase I to approval, compared to 10.0 years in the overall endocrine space.
• The distribution of clinical trials across Phase I–IV indicates that the majority of trials for hypogonadism have been in the early and mid-phases of development, with 54% of trials in Phase I–II, and 46% in Phase III–IV.
• The US has a substantial lead in the number of hypogonadism clinical trials globally. The UK leads the major European markets, while India has the top spot in Asia.
• Clinical trial activity in the hypogonadism space is dominated by completed trials. AbbVie has the highest number of completed clinical trials for hypogonadism, with eight trials.
• AbbVie leads industry sponsors with the highest overall number of clinical trials for hypogonadism, followed by GSK.